Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 12 528 M
EBIT 2017 3 733 M
Net income 2017 1 739 M
Debt 2017 12 866 M
Yield 2017 -
Sales 2018 13 094 M
EBIT 2018 4 044 M
Net income 2018 2 344 M
Debt 2018 10 939 M
Yield 2018 -
P/E ratio 2017 12,95
P/E ratio 2018 10,61
EV / Sales2017 2,67x
EV / Sales2018 2,41x
Capitalization 20 598 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted... 
Sector
Pharmaceuticals
Calendar
08/10Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/10 MYLAN : and Biocon Present Clinical Data on Insulin Glargine at the American Dia..
06/07 MYLAN : to Present at Goldman Sachs 38th Annual Global Healthcare Conference
06/07 Mylan defends chairman to ISS ahead of June 22 investor vote
06/06 JOHN HENDRICKSON : Drugmaker Perrigo says CEO Hendrickson plans to retire
06/05 MYLAN NV : Featured Company News - Mylan Launches Two New Generic Drugs: Generic..
06/02 MYLAN : Launches Generic Azilect® Tablets
06/02 MYLAN : Launches Generic Reclast® Injection
05/23 MYLAN : Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefe..
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
More news
Sector news : Pharmaceuticals - NEC
06/28 UK blue chips led lower by Hargreaves as strong pound takes toll
06/28DJVECTURA : In Asthma Collaboration With Novartis's Sandoz
06/28DJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
06/28DJMERCK AND : Today's Top Supply Chain and Logistics News From WSJ
06/28 Factbox - Companies hit by global ransomware attack on June 27
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 48,7 $
Spread / Average Target 27%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC20 598
JOHNSON & JOHNSON18.34%363 694
ROCHE HOLDING LTD.8.21%224 549
NOVARTIS12.55%222 848
PFIZER3.97%201 105
MERCK AND COMPANY11.33%179 263
More Results